ArticleFrontiers in pediatrics2026
Increasing incidence and severity of childhood-onset type 1 diabetes in Latvia during the COVID-19 pandemic.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During the COVID-19 pandemic in Latvia, there was a significant increase in new-onset childhood type 1 diabetes (T1D). The aim of this study is to analyze the influence of SARS-CoV-2 virus on initial manifestation of T1D and patterns of risk factors for disease development in children. Materials and methods: In the cross-sectional part of the study, 277 patients aged 1-17 years with new-onset T1D hospitalized in Children's Clinical University Hospital between 2017 and 2024 were selected and divided into two groups depending on COVID-19 history prior to T1D onset: (1) research group (past, laboratory-proven infection or positive SARS-CoV-2 antibodies at the time of hospitalization); (2) control group (negative COVID-19 history and prepandemic patients). Initial manifestation was evaluated by analyzing clinical presentation and blood gas tests. Among the risk factors, prenatal, dietary, and hereditary factors and infections were analyzed. Results: The rate of incidence of T1D increased by 37.6% during the COVID-19 pandemic in Latvia ( Conclusion: After exposure to SARS-CoV-2, patients in the cohort group had a more severe initial manifestation of T1D than patients without a history of COVID-19, which could not be attributed to the restrictions imposed by the pandemic or to other changes resulting from patient or primary care decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.